This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is the Options Market Predicting a Spike in Sorrento (SRNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody
by Zacks Equity Research
Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.
Company News for Sep 18, 2020
by Zacks Equity Research
Companies In The News Are: F, SRNE, JOBS, MET.
Implied Volatility Surging for Sorrento Therapeutics (SRNE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.
Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline
by Zacks Equity Research
Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.
Has Sorrento Therapeutics (SRNE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRNE) Outperforming Other Medical Stocks This Year?
Will Sorrento Therapeutics (SRNE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
Is Sorrento Therapeutics (SRNE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRNE) Outperforming Other Medical Stocks This Year?
Earnings Estimates Moving Higher for Sorrento Therapeutics (SRNE): Time to Buy?
by Zacks Equity Research
Sorrento Therapeutics (SRNE) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Implied Volatility Surging for Sorrento Therapeutics (SRNE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.
Sorrento Therapeutics (SRNE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Sorrento Therapeutics (SRNE) closed at $6.68, marking a +1.52% move from the previous day.
Find Strong Stocks Under $10 to Buy with this Screener
by Benjamin Rains
Check out this screener that helps investors find strong "cheap" stocks that are currently trading for under $10 a share...
Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sorrento Therapeutics (SRNE) closed at $7.29, marking a -1.22% move from the previous day.
Has Sorrento Therapeutics (SRNE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRNE) Outperforming Other Medical Stocks This Year?
Will Sorrento Therapeutics??? Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sorrento Therapeutics
Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.
Company News for May 27, 2020
by Zacks Equity Research
Companies In The News Are: EVFM, BNFT, SRNE, CLRB
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
Implied Volatility Surging for Sorrento Therapeutics (SRNE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.
Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Sorrento Therapeutics (SRNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately
Company News for Mar 23, 2020
by Zacks Equity Research
Companies In The News Are: BLPH, GNMK, WORK, SRNE
Earnings Preview: Sorrento Therapeutics (SRNE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.